On the 7th June, the US FDA held a special meeting and approved an experimental drug called aducanumab for the treatment of Alzheimer’s. This decision represents a major milestone for neurodegenerative research.
Researchers conducting the phase 3 ‘Exenatide PD3’ clinical trial have published the protocol of the study, which outlines the details of the trial. Cure Parkinson’s is supporting two sub-studies within the phase 3 trial.
In Parkinson’s, a cell protein called alpha-synuclein, which is abundant in dopamine-producing nerve cells, is known to clump together (or aggregate) and it is believed that this process could be toxic. Anle138b is a small molecule that has been designed to inhibit alpha-synuclein aggregation.
Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain genetic risk factors and Parkinson’s progression.
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson’s in people with diabetes.